查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587694

到 2030 年无标定阵列系统的全球市场预测：按类型、应用、最终用户和地区进行分析

Label-free Array Systems Market Forecasts to 2030 - Global Analysis By Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球无标定阵列系统市场规模将达到 15.9 亿美元，预计到 2030 年将达到 27.9 亿美元，预测期内复合年增长率为 9.8%。

无标定阵列系统是用于生物和化学研究的先进分析平台，用于研究生物分子之间的相互作用，无需萤光或放射性标记。这些系统利用各种检测方法，例如表面等离子共振（SPR）、石英晶共振器微天平（QCM）和光波导来即时监测结合事件。透过测量质量、屈光和共振频率的变化，研究人员可以深入了解分子相互作用、动力学和亲和性。

据世界卫生组织(WHO)称，预计2024年和2050年将出现超过3500万例新癌症病例，比2022年的2000万例增加77%。

对高性能和筛检的需求不断增长

传统的筛检方法通常依赖标籤或标籤，这可能会干扰生物相互作用或使分析变得复杂。相较之下，无标定技术利用表面等离子共振和电阻感测等技术来即时监测生物分子相互作用，而无需标记。这不仅加快了筛检过程，而且提供了更准确、更可靠的资料。随着研究人员的目标是测试更大的化合物库并提高通量，能够快速、灵敏地检测结合事件的无标定系统变得至关重要。

技术复杂性

儘管无标定阵列系统是生物感测和诊断领域一项有前途的技术，但其技术复杂性构成了重大挑战。这些系统依赖于检测生物分子之间的相互作用，而不使用萤光或放射性标记，这使得它们对于即时监测和分析很有吸引力。然而，感测器表面设计和优化的复杂性以及对高灵敏度和特异性的需求使它们的开发变得复杂。基准漂移和重复性等问题需要先进的校准技术和先进的资料处理演算法。

个人化医疗日益受到关注

对个人化医疗的日益关注极大地促进了无标定阵列系统的开发，该系统能够为个别患者量身定制精确的诊断和治疗策略。这些系统不需要萤光或放射性标记，可以即时监测生物交互作用，从而实现更准确、更有效率的分析。由于个人化医疗寻求根据患者独特的遗传和分子特征来优化治疗，无标定技术可以快速评估患者样本中的生物标记相互作用和药物反应。这种能力不仅加速了有效治疗方法的确定，而且还有助于透过专注于标靶治疗来最大限度地减少副作用。

监管挑战

无标定阵列系统可以即时监测生物相互作用，无需萤光或放射性标记，但面临阻碍其开发和商业化的重大监管挑战。一个主要障碍是缺乏验证和品管的标准化通讯协定，使得製造商难以满足监管要求。这些系统的复杂性需要对灵敏度、特异性和再现性等性能特征进行可靠的记录，这需要大量的资源。无标定技术的新颖性意味着监管机构可能尚未建立其评估框架，导致核准过程存在不确定性。

COVID-19 的影响

COVID-19 大流行对无标定阵列系统产生了重大影响，而无标记阵列系统对于生物和化学分析至关重要。疫情期间，许多研究设施和实验室面临关闭或访问限制，导致正在进行的计划和新技术的开发被推迟。这种混乱阻碍了无标定方法的发展，以便在不使用萤光标记的情况下准确检测和分析生物分子相互作用。随着重点转向与大流行相关的应急研究，研究倡议的资金减少，影响了该领域的创新。

表面等离子共振领域预计将在预测期内成为最大的领域

透过实现分子间相互作用的即时监测，表面等离子共振部分预计将在预测期内占据最大份额。 SPR 利用金属-电介质界面上电子表面等离子体连贯振盪的独特光学特性。当光以特定角度照射金属表面时，会引发等离子体激元，导致屈光发生可测量的变化。这种变化发生在抗原-抗体相互作用等结合事件期间，并且允许在不需要标记剂的情况下灵敏地检测生物分子。

预计生物分子交互作用领域在预测期内复合年增长率最高

透过整合创新技术，无需使用标籤即可即时监测分子间相互作用，生物分子相互作用领域预计将在预测期内快速成长。这项增强功能能够更准确、动态地评估生物分子交互作用，例如蛋白质-蛋白质、蛋白质-DNA 和配体-受体交互作用。此外，消除标记的需要减少了潜在的伪影并保留了生物分子的自然状态，从而产生更多的生物学相关资料。

比最大的地区

预计北美地区将在整个预测期内占据最大的市场份额。糖尿病、心血管疾病和癌症等慢性病需要持续监测和早期检测，这使得该地区对先进诊断技术的需求不断增长。无标定阵列系统不需要化学标记，因此具有多种优点，包括更短的测定时间和更低的成本。这使其对医疗保健提供者和患者都具有吸引力。此外，这些系统可以即时监测生物分子相互作用，这对于了解疾病进展和治疗反应至关重要。

复合年增长率最高的地区

据估计，欧洲在预测期内的复合年增长率最高。政府法规推动严格的品质和安全标准，并鼓励製造商创新和提高产品可靠性。透过制定明确的验证和性能指标指南，监管机构正在帮助医疗保健提供者和研究人员增强对无标定技术的信心。此外，旨在支持研究和开发的倡议（例如津贴和合作计划）正在推动该领域的进步。法律规范内对永续性和道德实践的重视也推动了环保材料和方法在无标定阵列系统製造中的整合。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 按产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球无标定阵列系统市场：按类型

  • 介绍
  • 生物层干扰
  • 表面等离子体共振
  • 原子力显微镜
  • 其他的

第六章全球无标定阵列系统市场：依应用分类

  • 介绍
  • 蛋白质界面分析
  • 药物发现
  • 抗体表征
  • 生物分子相互作用
  • 其他的

第七章全球无标定阵列系统市场：依最终使用者分类

  • 介绍
  • 製药和生物技术公司
  • 学术研究所
  • 合约研究组织
  • 其他的

第八章全球无标定阵列系统市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第九章 主要进展

  • 合约、伙伴关係、合作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第 10 章 公司概况

  • Agilent Technologies, Inc
  • Becton, Dickinson and Company
  • Berthold Technologies
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies, Inc
  • Illumina, Inc
  • Luminex Corporation
  • Mikroscan Technologies
  • Nanion Technologies
  • NanoString Technologies
  • Pall Corporation
  • PerkinElmer, Inc
  • Sartorius AG
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc
Product Code: SMRC27681

According to Stratistics MRC, the Global Label-free Array Systems Market is accounted for $1.59 billion in 2024 and is expected to reach $2.79 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Label-free array systems are advanced analytical platforms used in biological and chemical research to study interactions between biomolecules without the need for fluorescent or radioactive labels. These systems utilize various detection methods, such as surface plasmon resonance (SPR), quartz crystal microbalance (QCM), or optical waveguides, to monitor binding events in real-time. By measuring changes in mass, refractive index, or resonance frequency, researchers can gain insights into molecular interactions, kinetics, and affinities.

According to the World Health Organization (WHO), in 2024, over 35 million new cancer cases are predicted in 2050, a 77% increase from the 20 million cases in 2022.

Market Dynamics:

Driver:

Increased demand for high-throughput screening

Traditional screening methods often rely on labels or tags, which can interfere with biological interactions and add complexity to the analysis. In contrast, label-free technologies utilize techniques such as surface plasmon resonance and impedance sensing, allowing for real-time monitoring of biomolecular interactions without the need for labels. This not only accelerates the screening process but also provides more accurate and reliable data. As researchers aim to test larger compound libraries and increase throughput, label-free systems become indispensable, offering rapid and sensitive detection of binding events.

Restraint:

Technical complexity

Label-free array systems are promising technologies in biosensing and diagnostics, but their technical complexity poses significant challenges. These systems rely on detecting biomolecular interactions without the use of fluorescent or radioactive labels, making them attractive for real-time monitoring and analysis. However, the intricacies of designing and optimizing sensor surfaces, along with the need for high sensitivity and specificity, complicate their development. Issues such as signal-to-noise ratio, baseline drift, and reproducibility require sophisticated calibration methods and advanced data processing algorithms.

Opportunity:

Growing focus on personalized medicine

The growing emphasis on personalized medicine is substantially enhancing the development of label-free array systems, which enable precise diagnostics and therapeutic strategies tailored to individual patients. These systems allow for the real-time monitoring of biological interactions without the need for fluorescent or radioactive labels, leading to more accurate and efficient analyses. As personalized medicine seeks to optimize treatment based on a patient's unique genetic and molecular profile, label-free technologies can rapidly assess biomarker interactions and drug responses in a patient's sample. This capability not only accelerates the identification of effective treatments but also minimizes side effects by focusing on targeted therapies.

Threat:

Regulatory challenges

Label-free array systems, which enable real-time monitoring of biological interactions without the need for fluorescent or radioactive labels, face significant regulatory challenges that hinder their development and commercialization. One major obstacle is the lack of standardized protocols for validation and quality control, making it difficult for manufacturers to meet regulatory requirements. The intricate nature of these systems demands robust documentation of their performance characteristics, including sensitivity, specificity, and reproducibility, which can be resource-intensive. The novelty of label-free technologies means that regulatory bodies may not have established frameworks for their evaluation, leading to uncertainty in approval processes.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted label-free array systems, which are crucial for biological and chemical analysis. During the pandemic, many research facilities and laboratories faced shutdowns or restricted access, leading to delays in ongoing projects and a slowdown in the development of new technologies. This disruption hindered the progression of label-free methods, which rely on precise detection and analysis of biomolecular interactions without the use of fluorescent labels. Funding for research initiatives decreased as priorities shifted towards immediate pandemic-related studies, affecting innovation in this field.

The Surface Plasmon Resonance segment is expected to be the largest during the forecast period

Surface Plasmon Resonance segment is expected to dominate the largest share over the estimated period by enabling real-time monitoring of molecular interactions. SPR exploits the unique optical properties of surface plasmons-coherent oscillations of electrons at the interface between a metal and a dielectric. When light hits the metal surface at a specific angle, it induces these plasmons, resulting in a measurable change in the refractive index. This change occurs upon binding events, such as antigen-antibody interactions, allowing for sensitive detection of biomolecules without the need for labeling agents.

The Biomolecular Interactions segment is expected to have the highest CAGR during the forecast period

Biomolecular Interactions segment is estimated to grow at a rapid pace during the forecast period by integrating innovative technologies that enable real-time monitoring of molecular interactions without the need for labels. This enhancement allows for more accurate and dynamic assessments of biomolecular interactions, such as protein-protein, protein-DNA, and ligand-receptor interactions. Furthermore, the elimination of labeling also reduces potential artifacts and preserves the natural state of the biomolecules, resulting in more biologically relevant data.

Region with largest share:

North America region is poised to hold the largest share of the market throughout the extrapolated period. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require continuous monitoring and early detection, driving the regional need for advanced diagnostic technologies. Label-free array systems offer several advantages, including reduced assay times and lower costs, as they eliminate the need for chemical labels. This enhances their attractiveness for both healthcare providers and patients. Furthermore, these systems enable real-time monitoring of biomolecular interactions, which is essential for understanding disease progression and response to therapies.

Region with highest CAGR:

Europe region is estimated to witness the highest CAGR during the projected time frame. Government regulations promote stringent quality and safety standards, encouraging manufacturers to innovate and improve the reliability of their products. By establishing clear guidelines for validation and performance metrics, regulatory bodies help foster trust in label-free technologies among healthcare providers and researchers. Additionally, initiatives aimed at supporting research and development, such as funding grants and collaborative projects, are driving advancements in this area. The emphasis on sustainability and ethical practices within regulatory frameworks also encourages the integration of eco-friendly materials and methods in the production of label-free array systems.

Key players in the market

Some of the key players in Label-free Array Systems market include Agilent Technologies, Inc, Becton, Dickinson and Company, Berthold Technologies, Danaher Corporation, F. Hoffmann-La Roche AG, GE HealthCare Technologies, Inc, Illumina, Inc, Luminex Corporation, Mikroscan Technologies, Nanion Technologies, NanoString Technologies, Pall Corporation, PerkinElmer, Inc, Sartorius AG, Siemens Healthineers AG and Thermo Fisher Scientific, Inc.

Key Developments:

In December 2023, Danaher Corporation completed the acquisition of Abcam plc, a supplier of protein research tools for life sciences based in Cambridge, England. This acquisition enriched the label-free array systems of the company. Thus, it increased the sales and revenues of the company.

In May 2022, Sartorius AG unveiled the new Octet SF3, the company's 1st surface plasmon resonance solution. Due to the system's low base-line noise and drift, large injection volumes, and novel injection techniques, users may generate better kinetics and the affinity data short time period. Thus, it increased the product portfolio of the company.

Types Covered:

  • Bio-layer Interferometry
  • Surface Plasmon Resonance
  • Atomic Force Microscopy
  • Other Types

Applications Covered:

  • Protein Interface Analysis
  • Drug Discovery
  • Antibody Characterization
  • Biomolecular Interactions
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Label-free Array Systems Market, By Type

  • 5.1 Introduction
  • 5.2 Bio-layer Interferometry
  • 5.3 Surface Plasmon Resonance
  • 5.4 Atomic Force Microscopy
  • 5.5 Other Types

6 Global Label-free Array Systems Market, By Application

  • 6.1 Introduction
  • 6.2 Protein Interface Analysis
  • 6.3 Drug Discovery
  • 6.4 Antibody Characterization
  • 6.5 Biomolecular Interactions
  • 6.6 Other Applications

7 Global Label-free Array Systems Market, By End User

  • 7.1 Introduction
  • 7.2 Pharmaceutical & Biotechnology Companies
  • 7.3 Academic & Research Institutes
  • 7.4 Contract Research Organizations
  • 7.5 Other End Users

8 Global Label-free Array Systems Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Agilent Technologies, Inc
  • 10.2 Becton, Dickinson and Company
  • 10.3 Berthold Technologies
  • 10.4 Danaher Corporation
  • 10.5 F. Hoffmann-La Roche AG
  • 10.6 GE HealthCare Technologies, Inc
  • 10.7 Illumina, Inc
  • 10.8 Luminex Corporation
  • 10.9 Mikroscan Technologies
  • 10.10 Nanion Technologies
  • 10.11 NanoString Technologies
  • 10.12 Pall Corporation
  • 10.13 PerkinElmer, Inc
  • 10.14 Sartorius AG
  • 10.15 Siemens Healthineers AG
  • 10.16 Thermo Fisher Scientific, Inc

List of Tables

  • Table 1 Global Label-free Array Systems Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Label-free Array Systems Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global Label-free Array Systems Market Outlook, By Bio-layer Interferometry (2022-2030) ($MN)
  • Table 4 Global Label-free Array Systems Market Outlook, By Surface Plasmon Resonance (2022-2030) ($MN)
  • Table 5 Global Label-free Array Systems Market Outlook, By Atomic Force Microscopy (2022-2030) ($MN)
  • Table 6 Global Label-free Array Systems Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 7 Global Label-free Array Systems Market Outlook, By Application (2022-2030) ($MN)
  • Table 8 Global Label-free Array Systems Market Outlook, By Protein Interface Analysis (2022-2030) ($MN)
  • Table 9 Global Label-free Array Systems Market Outlook, By Drug Discovery (2022-2030) ($MN)
  • Table 10 Global Label-free Array Systems Market Outlook, By Antibody Characterization (2022-2030) ($MN)
  • Table 11 Global Label-free Array Systems Market Outlook, By Biomolecular Interactions (2022-2030) ($MN)
  • Table 12 Global Label-free Array Systems Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 13 Global Label-free Array Systems Market Outlook, By End User (2022-2030) ($MN)
  • Table 14 Global Label-free Array Systems Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 15 Global Label-free Array Systems Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 16 Global Label-free Array Systems Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 17 Global Label-free Array Systems Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 18 North America Label-free Array Systems Market Outlook, By Country (2022-2030) ($MN)
  • Table 19 North America Label-free Array Systems Market Outlook, By Type (2022-2030) ($MN)
  • Table 20 North America Label-free Array Systems Market Outlook, By Bio-layer Interferometry (2022-2030) ($MN)
  • Table 21 North America Label-free Array Systems Market Outlook, By Surface Plasmon Resonance (2022-2030) ($MN)
  • Table 22 North America Label-free Array Systems Market Outlook, By Atomic Force Microscopy (2022-2030) ($MN)
  • Table 23 North America Label-free Array Systems Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 24 North America Label-free Array Systems Market Outlook, By Application (2022-2030) ($MN)
  • Table 25 North America Label-free Array Systems Market Outlook, By Protein Interface Analysis (2022-2030) ($MN)
  • Table 26 North America Label-free Array Systems Market Outlook, By Drug Discovery (2022-2030) ($MN)
  • Table 27 North America Label-free Array Systems Market Outlook, By Antibody Characterization (2022-2030) ($MN)
  • Table 28 North America Label-free Array Systems Market Outlook, By Biomolecular Interactions (2022-2030) ($MN)
  • Table 29 North America Label-free Array Systems Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 30 North America Label-free Array Systems Market Outlook, By End User (2022-2030) ($MN)
  • Table 31 North America Label-free Array Systems Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 32 North America Label-free Array Systems Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 33 North America Label-free Array Systems Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 34 North America Label-free Array Systems Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 35 Europe Label-free Array Systems Market Outlook, By Country (2022-2030) ($MN)
  • Table 36 Europe Label-free Array Systems Market Outlook, By Type (2022-2030) ($MN)
  • Table 37 Europe Label-free Array Systems Market Outlook, By Bio-layer Interferometry (2022-2030) ($MN)
  • Table 38 Europe Label-free Array Systems Market Outlook, By Surface Plasmon Resonance (2022-2030) ($MN)
  • Table 39 Europe Label-free Array Systems Market Outlook, By Atomic Force Microscopy (2022-2030) ($MN)
  • Table 40 Europe Label-free Array Systems Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 41 Europe Label-free Array Systems Market Outlook, By Application (2022-2030) ($MN)
  • Table 42 Europe Label-free Array Systems Market Outlook, By Protein Interface Analysis (2022-2030) ($MN)
  • Table 43 Europe Label-free Array Systems Market Outlook, By Drug Discovery (2022-2030) ($MN)
  • Table 44 Europe Label-free Array Systems Market Outlook, By Antibody Characterization (2022-2030) ($MN)
  • Table 45 Europe Label-free Array Systems Market Outlook, By Biomolecular Interactions (2022-2030) ($MN)
  • Table 46 Europe Label-free Array Systems Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 47 Europe Label-free Array Systems Market Outlook, By End User (2022-2030) ($MN)
  • Table 48 Europe Label-free Array Systems Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 49 Europe Label-free Array Systems Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 50 Europe Label-free Array Systems Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 51 Europe Label-free Array Systems Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 52 Asia Pacific Label-free Array Systems Market Outlook, By Country (2022-2030) ($MN)
  • Table 53 Asia Pacific Label-free Array Systems Market Outlook, By Type (2022-2030) ($MN)
  • Table 54 Asia Pacific Label-free Array Systems Market Outlook, By Bio-layer Interferometry (2022-2030) ($MN)
  • Table 55 Asia Pacific Label-free Array Systems Market Outlook, By Surface Plasmon Resonance (2022-2030) ($MN)
  • Table 56 Asia Pacific Label-free Array Systems Market Outlook, By Atomic Force Microscopy (2022-2030) ($MN)
  • Table 57 Asia Pacific Label-free Array Systems Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 58 Asia Pacific Label-free Array Systems Market Outlook, By Application (2022-2030) ($MN)
  • Table 59 Asia Pacific Label-free Array Systems Market Outlook, By Protein Interface Analysis (2022-2030) ($MN)
  • Table 60 Asia Pacific Label-free Array Systems Market Outlook, By Drug Discovery (2022-2030) ($MN)
  • Table 61 Asia Pacific Label-free Array Systems Market Outlook, By Antibody Characterization (2022-2030) ($MN)
  • Table 62 Asia Pacific Label-free Array Systems Market Outlook, By Biomolecular Interactions (2022-2030) ($MN)
  • Table 63 Asia Pacific Label-free Array Systems Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 64 Asia Pacific Label-free Array Systems Market Outlook, By End User (2022-2030) ($MN)
  • Table 65 Asia Pacific Label-free Array Systems Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 66 Asia Pacific Label-free Array Systems Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 67 Asia Pacific Label-free Array Systems Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 68 Asia Pacific Label-free Array Systems Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 69 South America Label-free Array Systems Market Outlook, By Country (2022-2030) ($MN)
  • Table 70 South America Label-free Array Systems Market Outlook, By Type (2022-2030) ($MN)
  • Table 71 South America Label-free Array Systems Market Outlook, By Bio-layer Interferometry (2022-2030) ($MN)
  • Table 72 South America Label-free Array Systems Market Outlook, By Surface Plasmon Resonance (2022-2030) ($MN)
  • Table 73 South America Label-free Array Systems Market Outlook, By Atomic Force Microscopy (2022-2030) ($MN)
  • Table 74 South America Label-free Array Systems Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 75 South America Label-free Array Systems Market Outlook, By Application (2022-2030) ($MN)
  • Table 76 South America Label-free Array Systems Market Outlook, By Protein Interface Analysis (2022-2030) ($MN)
  • Table 77 South America Label-free Array Systems Market Outlook, By Drug Discovery (2022-2030) ($MN)
  • Table 78 South America Label-free Array Systems Market Outlook, By Antibody Characterization (2022-2030) ($MN)
  • Table 79 South America Label-free Array Systems Market Outlook, By Biomolecular Interactions (2022-2030) ($MN)
  • Table 80 South America Label-free Array Systems Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 81 South America Label-free Array Systems Market Outlook, By End User (2022-2030) ($MN)
  • Table 82 South America Label-free Array Systems Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 83 South America Label-free Array Systems Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 84 South America Label-free Array Systems Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 85 South America Label-free Array Systems Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 86 Middle East & Africa Label-free Array Systems Market Outlook, By Country (2022-2030) ($MN)
  • Table 87 Middle East & Africa Label-free Array Systems Market Outlook, By Type (2022-2030) ($MN)
  • Table 88 Middle East & Africa Label-free Array Systems Market Outlook, By Bio-layer Interferometry (2022-2030) ($MN)
  • Table 89 Middle East & Africa Label-free Array Systems Market Outlook, By Surface Plasmon Resonance (2022-2030) ($MN)
  • Table 90 Middle East & Africa Label-free Array Systems Market Outlook, By Atomic Force Microscopy (2022-2030) ($MN)
  • Table 91 Middle East & Africa Label-free Array Systems Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 92 Middle East & Africa Label-free Array Systems Market Outlook, By Application (2022-2030) ($MN)
  • Table 93 Middle East & Africa Label-free Array Systems Market Outlook, By Protein Interface Analysis (2022-2030) ($MN)
  • Table 94 Middle East & Africa Label-free Array Systems Market Outlook, By Drug Discovery (2022-2030) ($MN)
  • Table 95 Middle East & Africa Label-free Array Systems Market Outlook, By Antibody Characterization (2022-2030) ($MN)
  • Table 96 Middle East & Africa Label-free Array Systems Market Outlook, By Biomolecular Interactions (2022-2030) ($MN)
  • Table 97 Middle East & Africa Label-free Array Systems Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 98 Middle East & Africa Label-free Array Systems Market Outlook, By End User (2022-2030) ($MN)
  • Table 99 Middle East & Africa Label-free Array Systems Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 100 Middle East & Africa Label-free Array Systems Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 101 Middle East & Africa Label-free Array Systems Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 102 Middle East & Africa Label-free Array Systems Market Outlook, By Other End Users (2022-2030) ($MN)